A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Podofilox
PEV3A
The therapeutic efficacy of PEV3A can be decreased when used in combination with Pazopanib.
Podofilox
G17DT
The therapeutic efficacy of G17DT can be decreased when used in combination with Pazopanib.
Podofilox
Osimertinib
The serum concentration of Pazopanib can be decreased when it is combined with Osimertinib.
Podofilox
Methotrimeprazine
The metabolism of Pazopanib can be decreased when combined with Methotrimeprazine.
Podofilox
Lorcaserin
The metabolism of Lorcaserin can be decreased when combined with Pazopanib.
Podofilox
Rhein
The metabolism of Pazopanib can be decreased when combined with Rhein.
Podofilox
Dosulepin
The metabolism of Dosulepin can be decreased when combined with Pazopanib.
Podofilox
Ritanserin
The metabolism of Pazopanib can be decreased when combined with Ritanserin.
Podofilox
Manidipine
The metabolism of Pazopanib can be decreased when combined with Manidipine.
Podofilox
Phenylbutyric acid
The metabolism of Pazopanib can be decreased when combined with Phenylbutyric acid.
Podofilox
Vilazodone
The metabolism of Pazopanib can be decreased when combined with Vilazodone.
Podofilox
Sulfaphenazole
The metabolism of Pazopanib can be decreased when combined with Sulfaphenazole.
Podofilox
Lumefantrine
The metabolism of Lumefantrine can be decreased when combined with Pazopanib.
Podofilox
Panobinostat
The metabolism of Panobinostat can be decreased when combined with Pazopanib.
Podofilox
Pazufloxacin
The metabolism of Pazopanib can be decreased when combined with Pazufloxacin.
Podofilox
Relugolix
The risk or severity of QTc prolongation can be increased when Relugolix is combined with Pazopanib.
Podofilox
Fostemsavir
The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Pazopanib.
Podofilox
Lurasidone
The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Pazopanib.
Podofilox
Gallopamil
The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Pazopanib.
Podofilox
Inotersen
The risk or severity of QTc prolongation can be increased when Inotersen is combined with Pazopanib.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3